-

Viz.ai to Participate in Morgan Stanley 22nd Annual Healthcare Conference

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced Chris Mansi, M.D., CEO and Co-founder, will present at the Morgan Stanley 22nd Annual Global Healthcare Conference on Sept. 4, 2024 at 1:05 p.m. ET in New York, NY.

Dr. Mansi will share how Viz.ai is transforming last mile delivery of AI-powered workflows in healthcare with a broadly deployed AI safety net to ensure no patient is missed, helping providers and life sciences to bridge care gaps and increase patient access to life-saving treatments. With the growing need to reinvent the pharmaceutical commercial model as the Inflation Reduction Act puts pressure on drug prices, Viz.ai’s AI-Powered Care Accelerator is uniquely positioned to guide more patients to the right diagnosis, specialist, and treatment faster.

About Viz.ai

Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,600+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai One™ is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, Viz.ai One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.

Contacts

Viz.ai


Release Versions

Contacts

Social Media Profiles
More News From Viz.ai

Viz.ai Announces Strategic Collaboration to Expand Access to AI-Powered Subdural Hemorrhage Care

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a strategic commercialization collaboration with Johnson & Johnson to expand access to Viz.ai’s Subdural Hemorrhage software solution across hospitals in the United States for automated detection, labeling and quantification of subdural collections. By integrating the Viz Subdural solution into its neurovascular offerings, the company aims to support hospital...

Viz.ai Wins Gold Edison Award™ for Advancing AI-Driven Clinical Workflows to Improve Hemorrhage Care

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced that it won the Gold Edison Award 2026 for its AI-powered Viz Hemorrhage solution. This marks the company’s fourth Edison Award and reinforces Viz.ai’s leadership in building the agentic infrastructure that enables artificial intelligence to operate directly within hospitals. Viz.ai was recognized in the Health, Medical & Biotech category for its groundbreaki...

Viz.ai Earns Back-to-Back No. 1 Ranking in Black Book Survey of AI Clinical Decision Support Solutions

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced it has been ranked No. 1 in the Black Book Research survey of AI Clinical Decision Support solutions for the second consecutive year. Based on direct feedback from 1,237 healthcare professionals, including clinicians, administrators, and operational leaders across hospitals, health systems, and medical groups, the annual Black Book survey evaluates vendors on ent...
Back to Newsroom